Clinical trials: Endocrine Disorder
Irritable Bowel Syndrome
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
This FTIH study is designed to assess the safety, tolerability and pharmacokinetic (PK) of escalating single and repeat oral doses of GSK3352589 in normal healthy volunteers.
- Trial name
- NCT03154086
- Testing
- GSK3352589
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ovarian Cancer, Recurrent Cancer
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation…
- Trial name
- NCT05043922
- Testing
- CYH33
- Where
- 36 sites in China, Japan
- Volunteers
- 93 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Diabetes
Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)
Insulin therapy requires monitoring and frequent review of glucose levels to optimize dosing. Effective presentation and data analysis are essential.
- Trial name
- NCT00333853
- Testing
- OneTouch(r) UltraSmart(r)
- Where
- 7 sites in United States
- Volunteers
- 250 people
- Sponsor
- LifeScan
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Turner's Syndrome, Human Growth Hormone Deficiency
Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device
The purpose of this strictly observational, prospective, longitudinal study is to evaluate with sufficient precision the rate of overall treatment compliance from one year to 3 years of follow-up of the patients.
- Trial name
- ZOMAJET (NCT01306357)
- Testing
- Somatropin
- Where
- 17 sites in France
- Volunteers
- 87 people
- Sponsor
- Ferring Pharmaceuticals
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Male Hypogonadism
Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation
The purpose of the study is to determine the effect of food with various amounts of fat on the absorption of an oral testosterone undecanoate formulation.
- Trial name
- NCT00924612
- Testing
- Oral testosterone undecanoate (containing 300 mg T)
- Where
- 2 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Clarus Therapeutics, Inc.
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Diabetes, Healthy
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Europe. The aim of this clinical trial is to assess and compare the safety and tolerability, as assessed by adverse events after multiple subcutaneous doses of NN9535 in healthy male Japanese and…
- Trial name
- NCT00851773
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes
The purpose of this study was to compare the pharmacokinetic (PK) response after inhaled insulin administration with 3 different inhalation regimens and with subcutaneous insulin administration.
- Trial name
- Samba-01 (NCT02713841)
- Testing
- inhaled human insulin (INH), sc insulin lispro (LIS)
- Volunteers
- 12 people
- Sponsor
- Dance Biopharm Inc.
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Diabetes Mellitus, Type 2
A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg
To establish the bioequivalence between Glucobay ODT (Orally Disintegrating Tablet) 100 mg taken without or with water and the Glucobay standard tablet 100 mg taken with water.
- Trial name
- NCT01554631
- Testing
- Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
This is a an open-label, randomized, single dose, four-way crossover, multi-stage study enrolling 20 healthy adult male and female subjects per part.
- Trial name
- NCT01725672
- Testing
- Metformin, 500 mg extended release tablet, Metformin, 1000 mg extended release tablet, Glimepiride, 1 mg immediate release tablet
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study Conducted Over 3 Periods to Look at the Drug in the Body
A study conducted over 3 periods to look at the drug in the body.
- Trial name
- NCT01225939
- Testing
- AZD8329
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes
Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus
The aim of this study is to determine the System Accuracy and User Performance evaluation of the mentioned BGM systems by gaining a sufficient amount of measured data from capillary blood.
- Trial name
- NCT02439177
- Testing
- Blood glucose monitoring system (Omnitest 3), Blood glucose monitoring system (Omnitest 5)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- B. Braun Melsungen AG
Diabetes Mellitus, Type 2
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
- Trial name
- NCT02367131
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 419 people
- Sponsor
- Boehringer Ingelheim
Neuropathic Diabetic Ulcer - Foot
Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.
The purpose of this study is to assess the safety of the RedDress Wound Care System (RD1) in patients Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.
- Trial name
- NCT01396837
- Testing
- RedDress Wound Care System (RD1)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- RedDress Ltd.
Type 2 Diabetes Mellitus
Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional
This is a multi-center, prospective, non-pivotal, single arm, non-significant risk evaluation the Abbott Sensor Based Glucose Monitoring System - Pro across different stages of T2 diabetes management.
- Trial name
- NCT02336945
- Testing
- Abbott Sensor Based Glucose Monitoring System-Professional
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Abbott Diabetes Care
Ovarian Neoplasms, Peritoneal Neoplasms
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine.
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT05194072
- Testing
- Felmetatug Vedotin, Pembrolizumab
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 250 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Type 2 Diabetes Mellitus
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral…
- Trial name
- NCT00242372
- Testing
- Tesaglitazar 0.5, Insulin at least 30 units/day
- Where
- 71 sites in United States
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.